Dl. Kirkby et Ga. Higgins, CHARACTERIZATION OF PERFORANT PATH LESIONS IN RODENT MODELS OF MEMORYAND ATTENTION, European journal of neuroscience, 10(3), 1998, pp. 823-838
Early stage Alzheimer's disease (AD) pathology is associated with neur
odegeneration of systems within the temporal cortex, e.g. the entorhin
al cortex, perforant pathway and hippocampus. The perforant pathway pr
ovides the major neuronal input to the hippocampus from the entorhinal
cortex and thus relays multimodal sensory information derived from co
rtical zones into the hippocampus. The earliest symptoms of AD include
cognitive impairments, e.g. deficits in short-term memory and attenti
on. Consequently we have investigated the effect of bilateral knife cu
t lesions to the perforant path on cognition in rats using models meas
uring primarily short-term memory (operant delayed match to position t
ask), attention (serial five-choice reaction time task) and spatial le
arning (Morris water maze). Rats receiving bilateral perforant path le
sions showed normal neurological function and a mild hyperactivity. Th
e lesion produced little effect on attention assessed using the five-c
hoice task. In contrast, animals with equivalent lesions showed a robu
st delay-dependent deficit in the delayed match to position task. Spat
ial learning in the water maze task was also severely impaired. The de
lay-dependent deficit in the match to position task was not reversed b
y tacrine (3 mg/kg) pretreatment. The present data support a selective
impairment of cognitive function following perforant path lesions tha
t was confined to mnemonic rather than attentional processing. These f
indings complement primate and human studies identifying a critical ro
le of the perforant pathway and associated temporal lobe structures in
declarative memory. Degeneration of the perforant pathway is likely t
o contribute to the mnemonic deficits characteristic of early AD. The
failure of tacrine to ameliorate these deficits may be relevant to an
emerging clinical literature suggesting that cholinomimetic therapies
improve attentional rather than mnemonic function in AD.